Kestra Medical Technologies, Ltd. (KMTS) Stock Analysis and Metrics

Kestra Medical Technologies

NASDAQ: KMTS

$21.07 ▼ -0.50 (-2.32%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.14 Bn

P/E-8.63

P/S11.93

Div. Yield0.00

ROIC (Qtr)-0.02

Total Debt (Qtr)42.65 Mn

Revenue Growth (1y) (Qtr)66.18

Add ratio to table…

About

Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The company has developed and is commercializing its Cardiac Recovery System platform a comprehensive and advanced system that integrates monitoring therapeutic treatment digital health and patient support services into a single unified solution. The cornerstone of the Cardiac Recovery System platform is the ASSURE WCD a next generation wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the US. The ASSURE WCD automatically monitors elevated risk patients and if needed delivers a defibrillation shock to return the patient's heart to normal rhythm. The device was purpose-built to enhance patient comfort and compliance directly addressing key barriers to adoption associated with the only other commercially available wearable cardioverter defibrillator.

Kestra Medical Technologies, Ltd. generates revenue primarily through a lease business model for its ASSURE WCD as part of the Cardiac Recovery System platform. Patients are prescribed the device by healthcare providers for specific durations typically three months or longer. The company fits patients with the ASSURE WCD in hospital clinic or home settings and directly bills various third-party payors including Medicare Medicaid and private insurers for the lease period. In addition to the core ASSURE WCD the platform includes fully integrated digital solutions such as the ASSURE patient application for real-time mobile updates and compliance tracking the Kestra CareStation remote patient data platform for provider analytics and alert management Heart Alert Services and ASSURE Assist services for emergency response coordination and the recently FDA-cleared ASSURE wearable ECG for extended monitoring post-WCD therapy. These components work together to create a seamless patient and provider experience throughout the cardiac care continuum.

Kestra Medical Technologies, Ltd. operates in the wearable cardioverter defibrillator market which has historically been served by a single incumbent commercial product the LifeVest WCD marketed by ZOLL. Since the first WCD received approval in 2001 global WCD revenues have grown to $1.3 billion in 2023 with approximately 85% generated in the US market. Despite clinical proof of safety and efficacy WCD therapy remains significantly underutilized reaching only 14% of the eligible US patient population in 2023. The company attributes this low penetration to limitations of the incumbent device including high false alarm rates (reported at 46% for users) poor wearability due to a unisex-only garment and limited patient-provider connectivity. The ASSURE WCD differentiates itself through multiple clinical and functional advantages: it delivers a 170 joule shock for improved efficacy in high-defibrillation-threshold patients features gender-specific garment designs developed with an athletic and sportswear designer incorporates cushioned electrodes for enhanced electrocardiogram signal quality utilizes four-channel electrocardiography with Adaptive Patient Intelligence technology to reduce false alarms to approximately 6% of users and provides a minimum of 25 shocks for safety during cardiac events such as ventricular tachycardia storms. These innovations position the company to address the substantial unmet need in a market where the addressable opportunity is estimated at approximately $10 billion annually in the US and $14 billion in international markets based on patient epidemiology and reimbursement rate analyses.

Kestra Medical Technologies, Ltd. serves patients indicated for wearable cardioverter defibrillator therapy which includes individuals at risk for sudden cardiac arrest who are not candidates for or refuse implantable cardioverter defibrillator treatment. Based on the company's analysis of epidemiological data there are approximately 800,000 cardiac patients annually in the US who have experienced myocardial infarction or heart failure with low left ventricular ejection fraction making them eligible for WCD therapy. An additional approximately 50,000 patients each year qualify due to documented ventricular tachycardia ventricular fibrillation inherited cardiac conditions or temporary explantation of implantable cardioverter defibrillators. The company's customer base consists of healthcare providers who prescribe the ASSURE WCD including general cardiologists, interventional cardiologists, cardiac electrophysiologists, cardiothoracic surgeons, hospitalists, nurse practitioners, and physician assistants. As of April 30 2025 more than 20,000 patients have worn the ASSURE WCD since its full commercial launch in August 2022 demonstrating early adoption and the company has established commercial relationships with healthcare facilities across the United States ranging from major academic medical centers to community hospitals. The company maintains a direct sales force of approximately 80 representatives supported by over 300 contracted patient specialists who assist with device fitting and training nationwide.

Investment Thesis

▲ Bull case

KMTS is positioned to capture significant market share from the incumbent competitor through its superior clinical differentiation, as evidenced by the ACE PAS study showing 100% arrhythmia conversion and low false alarm rates, which directly addresses physician concerns about patient safety and compliance. The new FDA-cleared Assure system algorithm further strengthens this advantage by reducing both false alarms and inappropriate shocks, creating a tangible product differentiation that competitors cannot easily replicate. This clinical edge is critical because the market remains vastly underpenetrated, with six out of seven indicated patients not receiving WCD therapy, and KMTS’s ability to prove real-world efficacy through large-scale studies like ACE PAS is shifting clinician perception and driving adoption beyond mere share gains from existing accounts. The company’s math indicating 70-75% of prescription growth comes from winning market share within the installed base—rather than just new prescribers—confirms that its clinical superiority is resonating with physicians who are actively switching from the competitor, a trend that will accelerate as the sales force expands to 130 territories by fiscal year-end.
The strategic collaboration with BioBeat to integrate ambulatory blood pressure monitoring (ABPM) into the Assure platform represents a hidden catalyst that management underplayed during the call, despite its potential to unlock substantial new clinical value and expand the addressable market. With 72% of ACE PAS study patients being hypertensive, integrating ABPM directly addresses a major comorbidity in the cardiac recovery population, transforming the WCD from a pure arrhythmia protection device into a comprehensive cardiac monitoring solution. This integration could significantly increase physician prescribing rates by providing actionable diagnostic insights for hypertension management during guideline-directed medical therapy optimization, a period when patients are at elevated risk. Given that hypertension affects approximately 120 million Americans, this feature has broad applicability and could differentiate KMTS in a way that drives both higher adoption per prescriber and expansion into new clinical workflows, potentially increasing revenue per fit beyond current expectations.
KMTS’s gross margin trajectory is more robust than market expectations suggest, driven by structural advantages in its rental model that are just beginning to scale, with sequential expansion now in its ninth quarter and a clear path to 70%+ gross margins. The improvement is not merely cyclical but stems from volume leverage on depreciation, increasing revenue per fit from higher in-network billing (now in the low 80s% from 70% at IPO), and matured cost improvement programs on disposables that are now paying full benefits as old inventory is burned through. Management’s confidence in achieving 70%+ gross margins is underpinned by the rental model’s inherent economics, where fixed costs are spread over growing unit volumes, and the company’s ability to maintain pricing power due to clear product differentiation. This margin expansion will directly translate to improved operating leverage, as evidenced by the declining adjusted EBITDA loss relative to revenue growth, and could accelerate profitability sooner than anticipated if the sales force expansion to 130 territories yields higher-than-expected prescription volume without proportional cost increases.
The Federal Supply Schedule addition for VA hospitals and Florida Medicaid provider status are underappreciated market access wins that will drive sustained, high-margin growth in two large, high-penetration markets with minimal incremental sales effort. The VA covers 9 million members, nearly half over 65, and KMTS’s ability to now directly engage VA hospitals nationwide through its sales territories removes a major barrier that previously limited penetration in this segment. Similarly, Florida’s managed Medicaid plans cover nearly 90% of Medicaid enrollees, and securing contracts with two of the four largest plans eliminates a key obstacle that had previously forced KMTS to forgo reimbursement for a large portion of its potential patient base in its largest state by market share. These wins are not one-time events but foundational access improvements that will compound over time as the sales force ramps up in these territories, with Vaseem Mahboob noting the gross margin tailwind in Florida from previously uncompensated Medicaid business now becoming billable, directly boosting profitability without requiring new prescription volume.
The company’s updated fiscal year 2026 revenue guidance of $93 million (55% growth) is conservative relative to the underlying momentum, as evidenced by the 63% year-over-year revenue growth in Q3 and the accelerating WCD market expansion (low- to mid-teens % in 2025, up from ~8% at IPO). Management’s own commentary indicates that market growth is being driven by a combination of clinical evidence (ACE PAS and competitor studies), commercial footprint expansion, and the competitor’s realization that it must grow the overall market to compete—suggesting a self-reinforcing cycle where KMTS’s share gains are expanding the total addressable market. With the sales force targeting 130 territories by fiscal year-end (up from 100) and clinical specialists being added to anchor territories, the foundation for sustained double-digit growth is being laid, and the current guidance likely underestimates the impact of these investments on same-store sales productivity and new account activation beyond what is reflected in the conservative 55% full-year target.

KMTS is positioned to capture significant market share from the incumbent competitor through its superior clinical differentiation, as evidenced by the ACE PAS study showing 100% arrhythmia conversion and low false alarm rates, which directly addresses physician concerns about patient safety and compliance. The new FDA-cleared Assure system algorithm further strengthens this advantage by reducing both false alarms and inappropriate shocks, creating a tangible product differentiation that competitors cannot easily replicate. This clinical edge is critical because the market remains vastly underpenetrated, with six out of seven indicated patients not receiving WCD therapy, and KMTS’s ability to prove real-world efficacy through large-scale studies like ACE PAS is shifting clinician perception and driving adoption beyond mere share gains from existing accounts. The company’s math indicating 70-75% of prescription growth comes from winning market share within the installed base—rather than just new prescribers—confirms that its clinical superiority is resonating with physicians who are actively switching from the competitor, a trend that will accelerate as the sales force expands to 130 territories by fiscal year-end.
The strategic collaboration with BioBeat to integrate ambulatory blood pressure monitoring (ABPM) into the Assure platform represents a hidden catalyst that management underplayed during the call, despite its potential to unlock substantial new clinical value and expand the addressable market. With 72% of ACE PAS study patients being hypertensive, integrating ABPM directly addresses a major comorbidity in the cardiac recovery population, transforming the WCD from a pure arrhythmia protection device into a comprehensive cardiac monitoring solution. This integration could significantly increase physician prescribing rates by providing actionable diagnostic insights for hypertension management during guideline-directed medical therapy optimization, a period when patients are at elevated risk. Given that hypertension affects approximately 120 million Americans, this feature has broad applicability and could differentiate KMTS in a way that drives both higher adoption per prescriber and expansion into new clinical workflows, potentially increasing revenue per fit beyond current expectations.
KMTS’s gross margin trajectory is more robust than market expectations suggest, driven by structural advantages in its rental model that are just beginning to scale, with sequential expansion now in its ninth quarter and a clear path to 70%+ gross margins. The improvement is not merely cyclical but stems from volume leverage on depreciation, increasing revenue per fit from higher in-network billing (now in the low 80s% from 70% at IPO), and matured cost improvement programs on disposables that are now paying full benefits as old inventory is burned through. Management’s confidence in achieving 70%+ gross margins is underpinned by the rental model’s inherent economics, where fixed costs are spread over growing unit volumes, and the company’s ability to maintain pricing power due to clear product differentiation. This margin expansion will directly translate to improved operating leverage, as evidenced by the declining adjusted EBITDA loss relative to revenue growth, and could accelerate profitability sooner than anticipated if the sales force expansion to 130 territories yields higher-than-expected prescription volume without proportional cost increases.
The Federal Supply Schedule addition for VA hospitals and Florida Medicaid provider status are underappreciated market access wins that will drive sustained, high-margin growth in two large, high-penetration markets with minimal incremental sales effort. The VA covers 9 million members, nearly half over 65, and KMTS’s ability to now directly engage VA hospitals nationwide through its sales territories removes a major barrier that previously limited penetration in this segment. Similarly, Florida’s managed Medicaid plans cover nearly 90% of Medicaid enrollees, and securing contracts with two of the four largest plans eliminates a key obstacle that had previously forced KMTS to forgo reimbursement for a large portion of its potential patient base in its largest state by market share. These wins are not one-time events but foundational access improvements that will compound over time as the sales force ramps up in these territories, with Vaseem Mahboob noting the gross margin tailwind in Florida from previously uncompensated Medicaid business now becoming billable, directly boosting profitability without requiring new prescription volume.
The company’s updated fiscal year 2026 revenue guidance of $93 million (55% growth) is conservative relative to the underlying momentum, as evidenced by the 63% year-over-year revenue growth in Q3 and the accelerating WCD market expansion (low- to mid-teens % in 2025, up from ~8% at IPO). Management’s own commentary indicates that market growth is being driven by a combination of clinical evidence (ACE PAS and competitor studies), commercial footprint expansion, and the competitor’s realization that it must grow the overall market to compete—suggesting a self-reinforcing cycle where KMTS’s share gains are expanding the total addressable market. With the sales force targeting 130 territories by fiscal year-end (up from 100) and clinical specialists being added to anchor territories, the foundation for sustained double-digit growth is being laid, and the current guidance likely underestimates the impact of these investments on same-store sales productivity and new account activation beyond what is reflected in the conservative 55% full-year target.

▼ Bear case

KMTS’s path to profitability remains distant and uncertain, as the company continues to report widening GAAP net losses ($34.2 million in Q3 vs $21.8 million prior year) and adjusted EBITDA losses ($21.2 million vs $16.3 million), despite strong revenue growth, indicating that operating leverage is not yet materializing at the scale needed to offset investments in commercial expansion. The GAAP operating expenses of $47.7 million include $1.5 million in nonrecurring costs, but even excluding these and stock-based compensation, operating expenses rose to $36.1 million from $24.8 million year-over-year, driven by investments in sales force expansion and public company costs. With cash burn in the mid-$20 million range per quarter (excluding the BioBeat investment), the $291 million cash position provides only about 3-4 years of runway at current burn rates, and the company has not provided a clear timeline for when adjusted EBITDA will turn positive, raising concerns that the path to profitability may be longer than the market anticipates, especially if sales force productivity does not scale as expected.
The company’s reliance on winning market share from the installed base (70-75% of prescription growth per management) creates a significant vulnerability to competitive retaliation, as ZOLL’s recent product upgrades and focus on ease of doing business (order processing, insurance coverage, service level) could erode KMTS’s share gains if the competitor successfully leverages its entrenched relationships and scale to match or exceed KMTS’s clinical differentiation efforts. Management acknowledged they are not hearing impact from ZOLL’s new larger WCD rollout yet, but noted the competitor is in a “slow launch” and only a fraction of patients are being offered the product—suggesting that the full competitive threat has not yet materialized, and if ZOLL accelerates its rollout or improves its service model to counter KMTS’s clinical advantages, the current share shift trend could reverse, particularly given that the WCD market remains highly concentrated with a single dominant incumbent.
The integration of BioBeat’s ABPM technology, while promising, carries substantial execution risk and may not deliver the anticipated clinical or commercial benefits, as the collaboration involves co-development and a $5 million equity investment in MyoV (BioBeat’s parent), with no guarantee of successful integration, regulatory clearance for the combined product, or physician adoption. The technology is described as a “cuffless patch-worn” device, which introduces potential challenges related to user comfort, wear time compliance, and data accuracy in ambulatory settings—factors that could undermine its clinical utility if not rigorously validated. Furthermore, the focus on hypertension management, while relevant to 72% of ACE PAS patients, may not sufficiently incentivize physicians to prescribe WCDs more broadly, as hypertension is often managed separately in outpatient settings, and the added diagnostic value may not justify the complexity or cost of integrating another monitoring layer into the WCD workflow, especially if reimbursement for ABPM remains separate or unclear.
Gross margin expansion, while impressive sequentially, may be overstated and susceptible to reversal if cost improvement programs on disposables fail to sustain or if changes in payer mix negatively impact revenue per fit. The current gross margin of 52.6% is driven by a shift to in-network billing (low 80s% range), volume leverage on disposables, and the rental model’s depreciation benefits—yet the company acknowledged that over 3,000 payers exist in the U.S., meaning the long tail of regional and local payers remains a drag on revenue cycle efficiency. If in-network mix plateaus or declines due to challenges in contracting with smaller payers, or if cost savings from disposable initiatives are exhausted, the sequential margin expansion could stall, leaving the company vulnerable to margin pressure as it scales, particularly given that management’s 70%+ gross margin target is contingent on continued success in these areas, which may not be linear or guaranteed.
The Federal Supply Schedule and Florida Medicaid wins, while positive, may not translate to meaningful near-term revenue or margin impact due to lengthy sales cycles, administrative complexity in government contracting, and the need for significant territory-level execution to realize benefits. Management noted that the Florida Medicaid agreements will take time to “roll through” and will not be an overnight benefit, with Vaseem Mahboob stating it will be “something that we will see progress on quarter over quarter,” implying a quarter over quarter.” Similarly, the VA rollout is described as territory-by-territory, with wins only seen in the “last four to six weeks,” suggesting early-stage adoption that may not scale quickly. Given that these are large, bureaucratic institutions with lengthy procurement processes, the revenue contribution from these channels may be delayed and incremental, failing to meaningfully accelerate growth in the near term despite the strategic importance highlighted by management.

KMTS’s path to profitability remains distant and uncertain, as the company continues to report widening GAAP net losses ($34.2 million in Q3 vs $21.8 million prior year) and adjusted EBITDA losses ($21.2 million vs $16.3 million), despite strong revenue growth, indicating that operating leverage is not yet materializing at the scale needed to offset investments in commercial expansion. The GAAP operating expenses of $47.7 million include $1.5 million in nonrecurring costs, but even excluding these and stock-based compensation, operating expenses rose to $36.1 million from $24.8 million year-over-year, driven by investments in sales force expansion and public company costs. With cash burn in the mid-$20 million range per quarter (excluding the BioBeat investment), the $291 million cash position provides only about 3-4 years of runway at current burn rates, and the company has not provided a clear timeline for when adjusted EBITDA will turn positive, raising concerns that the path to profitability may be longer than the market anticipates, especially if sales force productivity does not scale as expected.
The company’s reliance on winning market share from the installed base (70-75% of prescription growth per management) creates a significant vulnerability to competitive retaliation, as ZOLL’s recent product upgrades and focus on ease of doing business (order processing, insurance coverage, service level) could erode KMTS’s share gains if the competitor successfully leverages its entrenched relationships and scale to match or exceed KMTS’s clinical differentiation efforts. Management acknowledged they are not hearing impact from ZOLL’s new larger WCD rollout yet, but noted the competitor is in a “slow launch” and only a fraction of patients are being offered the product—suggesting that the full competitive threat has not yet materialized, and if ZOLL accelerates its rollout or improves its service model to counter KMTS’s clinical advantages, the current share shift trend could reverse, particularly given that the WCD market remains highly concentrated with a single dominant incumbent.
The integration of BioBeat’s ABPM technology, while promising, carries substantial execution risk and may not deliver the anticipated clinical or commercial benefits, as the collaboration involves co-development and a $5 million equity investment in MyoV (BioBeat’s parent), with no guarantee of successful integration, regulatory clearance for the combined product, or physician adoption. The technology is described as a “cuffless patch-worn” device, which introduces potential challenges related to user comfort, wear time compliance, and data accuracy in ambulatory settings—factors that could undermine its clinical utility if not rigorously validated. Furthermore, the focus on hypertension management, while relevant to 72% of ACE PAS patients, may not sufficiently incentivize physicians to prescribe WCDs more broadly, as hypertension is often managed separately in outpatient settings, and the added diagnostic value may not justify the complexity or cost of integrating another monitoring layer into the WCD workflow, especially if reimbursement for ABPM remains separate or unclear.
Gross margin expansion, while impressive sequentially, may be overstated and susceptible to reversal if cost improvement programs on disposables fail to sustain or if changes in payer mix negatively impact revenue per fit. The current gross margin of 52.6% is driven by a shift to in-network billing (low 80s% range), volume leverage on disposables, and the rental model’s depreciation benefits—yet the company acknowledged that over 3,000 payers exist in the U.S., meaning the long tail of regional and local payers remains a drag on revenue cycle efficiency. If in-network mix plateaus or declines due to challenges in contracting with smaller payers, or if cost savings from disposable initiatives are exhausted, the sequential margin expansion could stall, leaving the company vulnerable to margin pressure as it scales, particularly given that management’s 70%+ gross margin target is contingent on continued success in these areas, which may not be linear or guaranteed.
The Federal Supply Schedule and Florida Medicaid wins, while positive, may not translate to meaningful near-term revenue or margin impact due to lengthy sales cycles, administrative complexity in government contracting, and the need for significant territory-level execution to realize benefits. Management noted that the Florida Medicaid agreements will take time to “roll through” and will not be an overnight benefit, with Vaseem Mahboob stating it will be “something that we will see progress on quarter over quarter,” implying a quarter over quarter.” Similarly, the VA rollout is described as territory-by-territory, with wins only seen in the “last four to six weeks,” suggesting early-stage adoption that may not scale quickly. Given that these are large, bureaucratic institutions with lengthy procurement processes, the revenue contribution from these channels may be delayed and incremental, failing to meaningfully accelerate growth in the near term despite the strategic importance highlighted by management.

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password